Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma

Scott D. Walter, Daniel L. Chao, William J Feuer, Joyce Schiffman, Devron H. Char, J. William Harbour

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

IMPORTANCE Uveal melanoma (UM) can be divided into prognostically significant subgroups based on a prospectively validated and widely used 15-gene expression profile (GEP) test. Class 1 UMs have a low risk and class 2 UMs have a high risk formetastasis. OBJECTIVE To determine whether any clinicopathologic factors provide independent prognostic information that may enhance the accuracy of the GEP classification. DESIGN, SETTING, AND PARTICIPANTS This retrospective observational study performed at 2 ocular oncology referral centers included 339 patients in a primary cohort and 241 patients in a validation cohort. Both cohorts had a diagnosis of UM arising from the ciliary body and/or choroid. All patients underwent tumor biopsy for GEP prognostic testing. Clinicopathologic variables included patient age and sex, tumor thickness, largest basal tumor diameter (LBD), ciliary body involvement, and pathologic cell type. Patients from the primary cohort were enrolled from November 1, 1998, to March 16, 2012; from the validation cohort, from November 4, 1996, to November 7, 2013. Follow-up for the primary cohort was completed on August 18, 2013; for the validation cohort, December 10, 2013. Data were analyzed from November 12, 2013, to November 25, 2015. MAIN OUTCOME AND MEASURES Progression-free survival (PFS). The secondary outcomewas overall survival. RESULTS The primary cohort included 339 patients (175 women [51.6%]; mean [SD] age, 61.8 [13.6] years). The most significant prognostic factor was GEP classification (exp[b], 10.33; 95%CI, 4.30-24.84; P < .001). The only other variable that provided independent prognostic information was LBD (exp[b], 1.13; 95%CI, 1.02-1.26; P = .02). Among class 2 UMs, LBD showed a modest but significant association with PFS (exp[b], 1.13; 95%CI, 1.04-1.24; P = .005). The 5-year actuarial metastasis-free survival estimates (SE) were 97%(3%) for class 1 UMs with LBD of less than 12 mm, 90% (4%) for class 1 UMs with LBD of at least 12 mm, 90% (9%) for class 2 UMs with LBD of less than 12 mm, and 30% (7%) for class 2 UMs with LBDs of at least 12 mm. The independent prognostic value of LBD and the 12-mm LBD cutoff were corroborated in the independent validation 241-patient cohort. CONCLUSIONS AND RELEVANCE Class 2 UMs had better prognosis when the LBD was less than 12mmat the time of treatment. These findings could have important implications for patient counseling, primary tumor treatment, clinical trial enrollment,metastatic surveillance, and adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)734-740
Number of pages7
JournalJAMA Ophthalmology
Volume134
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Transcriptome
Neoplasms
Ciliary Body
Disease-Free Survival
Uveal melanoma
Survival
Choroid
Observational Studies
Counseling
Therapeutics
Referral and Consultation
Retrospective Studies
Outcome Assessment (Health Care)
Clinical Trials
Neoplasm Metastasis
Biopsy

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma. / Walter, Scott D.; Chao, Daniel L.; Feuer, William J; Schiffman, Joyce; Char, Devron H.; William Harbour, J.

In: JAMA Ophthalmology, Vol. 134, No. 7, 01.07.2016, p. 734-740.

Research output: Contribution to journalArticle

Walter, Scott D. ; Chao, Daniel L. ; Feuer, William J ; Schiffman, Joyce ; Char, Devron H. ; William Harbour, J. / Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma. In: JAMA Ophthalmology. 2016 ; Vol. 134, No. 7. pp. 734-740.
@article{3a8c034dc2e6465aa45551251eccaede,
title = "Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma",
abstract = "IMPORTANCE Uveal melanoma (UM) can be divided into prognostically significant subgroups based on a prospectively validated and widely used 15-gene expression profile (GEP) test. Class 1 UMs have a low risk and class 2 UMs have a high risk formetastasis. OBJECTIVE To determine whether any clinicopathologic factors provide independent prognostic information that may enhance the accuracy of the GEP classification. DESIGN, SETTING, AND PARTICIPANTS This retrospective observational study performed at 2 ocular oncology referral centers included 339 patients in a primary cohort and 241 patients in a validation cohort. Both cohorts had a diagnosis of UM arising from the ciliary body and/or choroid. All patients underwent tumor biopsy for GEP prognostic testing. Clinicopathologic variables included patient age and sex, tumor thickness, largest basal tumor diameter (LBD), ciliary body involvement, and pathologic cell type. Patients from the primary cohort were enrolled from November 1, 1998, to March 16, 2012; from the validation cohort, from November 4, 1996, to November 7, 2013. Follow-up for the primary cohort was completed on August 18, 2013; for the validation cohort, December 10, 2013. Data were analyzed from November 12, 2013, to November 25, 2015. MAIN OUTCOME AND MEASURES Progression-free survival (PFS). The secondary outcomewas overall survival. RESULTS The primary cohort included 339 patients (175 women [51.6{\%}]; mean [SD] age, 61.8 [13.6] years). The most significant prognostic factor was GEP classification (exp[b], 10.33; 95{\%}CI, 4.30-24.84; P < .001). The only other variable that provided independent prognostic information was LBD (exp[b], 1.13; 95{\%}CI, 1.02-1.26; P = .02). Among class 2 UMs, LBD showed a modest but significant association with PFS (exp[b], 1.13; 95{\%}CI, 1.04-1.24; P = .005). The 5-year actuarial metastasis-free survival estimates (SE) were 97{\%}(3{\%}) for class 1 UMs with LBD of less than 12 mm, 90{\%} (4{\%}) for class 1 UMs with LBD of at least 12 mm, 90{\%} (9{\%}) for class 2 UMs with LBD of less than 12 mm, and 30{\%} (7{\%}) for class 2 UMs with LBDs of at least 12 mm. The independent prognostic value of LBD and the 12-mm LBD cutoff were corroborated in the independent validation 241-patient cohort. CONCLUSIONS AND RELEVANCE Class 2 UMs had better prognosis when the LBD was less than 12mmat the time of treatment. These findings could have important implications for patient counseling, primary tumor treatment, clinical trial enrollment,metastatic surveillance, and adjuvant therapy.",
author = "Walter, {Scott D.} and Chao, {Daniel L.} and Feuer, {William J} and Joyce Schiffman and Char, {Devron H.} and {William Harbour}, J.",
year = "2016",
month = "7",
day = "1",
doi = "10.1001/jamaophthalmol.2016.0913",
language = "English (US)",
volume = "134",
pages = "734--740",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "7",

}

TY - JOUR

T1 - Prognostic implications of tumor diameter in association with gene expression profile for uveal melanoma

AU - Walter, Scott D.

AU - Chao, Daniel L.

AU - Feuer, William J

AU - Schiffman, Joyce

AU - Char, Devron H.

AU - William Harbour, J.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - IMPORTANCE Uveal melanoma (UM) can be divided into prognostically significant subgroups based on a prospectively validated and widely used 15-gene expression profile (GEP) test. Class 1 UMs have a low risk and class 2 UMs have a high risk formetastasis. OBJECTIVE To determine whether any clinicopathologic factors provide independent prognostic information that may enhance the accuracy of the GEP classification. DESIGN, SETTING, AND PARTICIPANTS This retrospective observational study performed at 2 ocular oncology referral centers included 339 patients in a primary cohort and 241 patients in a validation cohort. Both cohorts had a diagnosis of UM arising from the ciliary body and/or choroid. All patients underwent tumor biopsy for GEP prognostic testing. Clinicopathologic variables included patient age and sex, tumor thickness, largest basal tumor diameter (LBD), ciliary body involvement, and pathologic cell type. Patients from the primary cohort were enrolled from November 1, 1998, to March 16, 2012; from the validation cohort, from November 4, 1996, to November 7, 2013. Follow-up for the primary cohort was completed on August 18, 2013; for the validation cohort, December 10, 2013. Data were analyzed from November 12, 2013, to November 25, 2015. MAIN OUTCOME AND MEASURES Progression-free survival (PFS). The secondary outcomewas overall survival. RESULTS The primary cohort included 339 patients (175 women [51.6%]; mean [SD] age, 61.8 [13.6] years). The most significant prognostic factor was GEP classification (exp[b], 10.33; 95%CI, 4.30-24.84; P < .001). The only other variable that provided independent prognostic information was LBD (exp[b], 1.13; 95%CI, 1.02-1.26; P = .02). Among class 2 UMs, LBD showed a modest but significant association with PFS (exp[b], 1.13; 95%CI, 1.04-1.24; P = .005). The 5-year actuarial metastasis-free survival estimates (SE) were 97%(3%) for class 1 UMs with LBD of less than 12 mm, 90% (4%) for class 1 UMs with LBD of at least 12 mm, 90% (9%) for class 2 UMs with LBD of less than 12 mm, and 30% (7%) for class 2 UMs with LBDs of at least 12 mm. The independent prognostic value of LBD and the 12-mm LBD cutoff were corroborated in the independent validation 241-patient cohort. CONCLUSIONS AND RELEVANCE Class 2 UMs had better prognosis when the LBD was less than 12mmat the time of treatment. These findings could have important implications for patient counseling, primary tumor treatment, clinical trial enrollment,metastatic surveillance, and adjuvant therapy.

AB - IMPORTANCE Uveal melanoma (UM) can be divided into prognostically significant subgroups based on a prospectively validated and widely used 15-gene expression profile (GEP) test. Class 1 UMs have a low risk and class 2 UMs have a high risk formetastasis. OBJECTIVE To determine whether any clinicopathologic factors provide independent prognostic information that may enhance the accuracy of the GEP classification. DESIGN, SETTING, AND PARTICIPANTS This retrospective observational study performed at 2 ocular oncology referral centers included 339 patients in a primary cohort and 241 patients in a validation cohort. Both cohorts had a diagnosis of UM arising from the ciliary body and/or choroid. All patients underwent tumor biopsy for GEP prognostic testing. Clinicopathologic variables included patient age and sex, tumor thickness, largest basal tumor diameter (LBD), ciliary body involvement, and pathologic cell type. Patients from the primary cohort were enrolled from November 1, 1998, to March 16, 2012; from the validation cohort, from November 4, 1996, to November 7, 2013. Follow-up for the primary cohort was completed on August 18, 2013; for the validation cohort, December 10, 2013. Data were analyzed from November 12, 2013, to November 25, 2015. MAIN OUTCOME AND MEASURES Progression-free survival (PFS). The secondary outcomewas overall survival. RESULTS The primary cohort included 339 patients (175 women [51.6%]; mean [SD] age, 61.8 [13.6] years). The most significant prognostic factor was GEP classification (exp[b], 10.33; 95%CI, 4.30-24.84; P < .001). The only other variable that provided independent prognostic information was LBD (exp[b], 1.13; 95%CI, 1.02-1.26; P = .02). Among class 2 UMs, LBD showed a modest but significant association with PFS (exp[b], 1.13; 95%CI, 1.04-1.24; P = .005). The 5-year actuarial metastasis-free survival estimates (SE) were 97%(3%) for class 1 UMs with LBD of less than 12 mm, 90% (4%) for class 1 UMs with LBD of at least 12 mm, 90% (9%) for class 2 UMs with LBD of less than 12 mm, and 30% (7%) for class 2 UMs with LBDs of at least 12 mm. The independent prognostic value of LBD and the 12-mm LBD cutoff were corroborated in the independent validation 241-patient cohort. CONCLUSIONS AND RELEVANCE Class 2 UMs had better prognosis when the LBD was less than 12mmat the time of treatment. These findings could have important implications for patient counseling, primary tumor treatment, clinical trial enrollment,metastatic surveillance, and adjuvant therapy.

UR - http://www.scopus.com/inward/record.url?scp=84978472524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978472524&partnerID=8YFLogxK

U2 - 10.1001/jamaophthalmol.2016.0913

DO - 10.1001/jamaophthalmol.2016.0913

M3 - Article

C2 - 27123792

AN - SCOPUS:84978472524

VL - 134

SP - 734

EP - 740

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 7

ER -